Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics : a case-control study. / Jørgensen, Anders; Knorr, Ulla Benedichte Søsted; Soendergaard, Mia Greisen; Lykkesfeldt, Jens; Fink-Jensen, Anders; Poulsen, Henrik Enghusen; Jørgensen, Martin Balslev; Olsen, Niels Vidiendal; Staalsø, Jonatan Myrup.

In: B M C Psychiatry, Vol. 15, 67, 2015.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Jørgensen, A, Knorr, UBS, Soendergaard, MG, Lykkesfeldt, J, Fink-Jensen, A, Poulsen, HE, Jørgensen, MB, Olsen, NV & Staalsø, JM 2015, 'Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study', B M C Psychiatry, vol. 15, 67. https://doi.org/10.1186/s12888-015-0455-4

APA

Jørgensen, A., Knorr, U. B. S., Soendergaard, M. G., Lykkesfeldt, J., Fink-Jensen, A., Poulsen, H. E., ... Staalsø, J. M. (2015). Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study. B M C Psychiatry, 15, [67]. https://doi.org/10.1186/s12888-015-0455-4

Vancouver

Jørgensen A, Knorr UBS, Soendergaard MG, Lykkesfeldt J, Fink-Jensen A, Poulsen HE et al. Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study. B M C Psychiatry. 2015;15. 67. https://doi.org/10.1186/s12888-015-0455-4

Author

Jørgensen, Anders ; Knorr, Ulla Benedichte Søsted ; Soendergaard, Mia Greisen ; Lykkesfeldt, Jens ; Fink-Jensen, Anders ; Poulsen, Henrik Enghusen ; Jørgensen, Martin Balslev ; Olsen, Niels Vidiendal ; Staalsø, Jonatan Myrup. / Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics : a case-control study. In: B M C Psychiatry. 2015 ; Vol. 15.

Bibtex

@article{36deab6abd7c456d8e3b20db22e59b34,
title = "Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study",
abstract = "BACKGROUND: Schizophrenia is associated with increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of the nitric oxide synthase, and the L-arginine:ADMA ratio are markers of endothelial dysfunction that predict mortality and adverse outcome in a range of cardiovascular disorders. Increased ADMA levels may also lead to increased oxidative stress. We hypothesized that ADMA and the L-arginine:ADMA ratio are increased in somatically healthy schizophrenia patients treated with atypical antipsychotics (AAP), and that the ADMA and the L-arginine: ADMA ratio are positively correlated to measures of oxidative stress.METHODS: We included 40 schizophrenia patients treated with AAP, but without somatic disease or drug abuse, and 40 healthy controls. Plasma concentrations of ADMA and L-arginine were determined by high-performance liquid chromatography. Data were related to markers of systemic oxidative stress on DNA, RNA and lipids, as well as measures of medication load, duration of disease and current symptomatology.RESULTS: Plasma ADMA and the L-arginine:ADMA ratio did not differ between schizophrenia patients and controls. Furthermore, ADMA and the L-arginine:ADMA ratio showed no correlations with oxidative stress markers, medication load, or Positive and Negative Syndrome Scale scores.CONCLUSIONS: Schizophrenia and treatment with AAP was not associated with increased levels of plasma ADMA or the L-arginine:ADMA ratio. Furthermore, plasma levels of ADMA were not associated with levels of systemic oxidative stress in vivo.",
author = "Anders J{\o}rgensen and Knorr, {Ulla Benedichte S{\o}sted} and Soendergaard, {Mia Greisen} and Jens Lykkesfeldt and Anders Fink-Jensen and Poulsen, {Henrik Enghusen} and J{\o}rgensen, {Martin Balslev} and Olsen, {Niels Vidiendal} and Staals{\o}, {Jonatan Myrup}",
year = "2015",
doi = "10.1186/s12888-015-0455-4",
language = "English",
volume = "15",
journal = "B M C Psychiatry",
issn = "1471-244X",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics

T2 - a case-control study

AU - Jørgensen, Anders

AU - Knorr, Ulla Benedichte Søsted

AU - Soendergaard, Mia Greisen

AU - Lykkesfeldt, Jens

AU - Fink-Jensen, Anders

AU - Poulsen, Henrik Enghusen

AU - Jørgensen, Martin Balslev

AU - Olsen, Niels Vidiendal

AU - Staalsø, Jonatan Myrup

PY - 2015

Y1 - 2015

N2 - BACKGROUND: Schizophrenia is associated with increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of the nitric oxide synthase, and the L-arginine:ADMA ratio are markers of endothelial dysfunction that predict mortality and adverse outcome in a range of cardiovascular disorders. Increased ADMA levels may also lead to increased oxidative stress. We hypothesized that ADMA and the L-arginine:ADMA ratio are increased in somatically healthy schizophrenia patients treated with atypical antipsychotics (AAP), and that the ADMA and the L-arginine: ADMA ratio are positively correlated to measures of oxidative stress.METHODS: We included 40 schizophrenia patients treated with AAP, but without somatic disease or drug abuse, and 40 healthy controls. Plasma concentrations of ADMA and L-arginine were determined by high-performance liquid chromatography. Data were related to markers of systemic oxidative stress on DNA, RNA and lipids, as well as measures of medication load, duration of disease and current symptomatology.RESULTS: Plasma ADMA and the L-arginine:ADMA ratio did not differ between schizophrenia patients and controls. Furthermore, ADMA and the L-arginine:ADMA ratio showed no correlations with oxidative stress markers, medication load, or Positive and Negative Syndrome Scale scores.CONCLUSIONS: Schizophrenia and treatment with AAP was not associated with increased levels of plasma ADMA or the L-arginine:ADMA ratio. Furthermore, plasma levels of ADMA were not associated with levels of systemic oxidative stress in vivo.

AB - BACKGROUND: Schizophrenia is associated with increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of the nitric oxide synthase, and the L-arginine:ADMA ratio are markers of endothelial dysfunction that predict mortality and adverse outcome in a range of cardiovascular disorders. Increased ADMA levels may also lead to increased oxidative stress. We hypothesized that ADMA and the L-arginine:ADMA ratio are increased in somatically healthy schizophrenia patients treated with atypical antipsychotics (AAP), and that the ADMA and the L-arginine: ADMA ratio are positively correlated to measures of oxidative stress.METHODS: We included 40 schizophrenia patients treated with AAP, but without somatic disease or drug abuse, and 40 healthy controls. Plasma concentrations of ADMA and L-arginine were determined by high-performance liquid chromatography. Data were related to markers of systemic oxidative stress on DNA, RNA and lipids, as well as measures of medication load, duration of disease and current symptomatology.RESULTS: Plasma ADMA and the L-arginine:ADMA ratio did not differ between schizophrenia patients and controls. Furthermore, ADMA and the L-arginine:ADMA ratio showed no correlations with oxidative stress markers, medication load, or Positive and Negative Syndrome Scale scores.CONCLUSIONS: Schizophrenia and treatment with AAP was not associated with increased levels of plasma ADMA or the L-arginine:ADMA ratio. Furthermore, plasma levels of ADMA were not associated with levels of systemic oxidative stress in vivo.

U2 - 10.1186/s12888-015-0455-4

DO - 10.1186/s12888-015-0455-4

M3 - Journal article

VL - 15

JO - B M C Psychiatry

JF - B M C Psychiatry

SN - 1471-244X

M1 - 67

ER -

ID: 137167991